|Articles|November 7, 2005

PharmRep06Rates

External Link - article-196844.pdf

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: FDA Approves Baxdrostat

ByNicholas Jacobus

May 18th 2026

FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report

ByNicholas Jacobus

May 18th 2026

BaxHTN Phase III results show Baxfendy produced statistically significant and clinically meaningful reduction in systolic blood pressure in patients with uncontrolled or resistant hypertension. Credit: Stock.Adobe.com/meenkulathiamma.

FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry

ByPharmaceutical Executive Editorial Staff

May 18th 2026

Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates

ByNicholas Jacobus

May 18th 2026

“These approvals mark an important step forward, expanding the possibility of cure to more patients for the first time in many years and positioning Enhertu as a foundational treatment in early breast cancer.” Credit: Stock.Adobe.com/jittawit.21

FDA Expands Enhertu in Early HER2-Positive Breast Cancer

ByPharmaceutical Executive Editorial Staff

May 18th 2026

PharmRep06Rates

Related Content

Pharmaceutical Executive Daily: FDA Approves Baxdrostat

FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report

FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry

Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates

FDA Expands Enhertu in Early HER2-Positive Breast Cancer

Trending on PharmExec

FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report

Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates

How Pharma is Adjusting Strategies for Changing Dynamics at FDA

FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry

FDA’s New Pilot Program and Real-Time Review of Clinical Data